RT Journal Article
SR Electronic
T1 Impact of COVID-19 on mortality in coastal Kenya: a longitudinal open cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.12.22281019
DO 10.1101/2022.10.12.22281019
A1 Otiende, M
A1 Nyaguara, A
A1 Bottomley, C
A1 Walumbe, D
A1 Mochamah, G
A1 Amadi, D
A1 Nyundo, C
A1 Kagucia, EW
A1 Etyang, AO
A1 Adetifa, IMO
A1 Brand, SPC
A1 Maitha, E
A1 Chondo, E
A1 Nzomo, E
A1 Aman, R
A1 Mwangangi, M
A1 Amoth, P
A1 Kasera, K
A1 Ng’ang’a, W
A1 Barasa, E
A1 Tsofa, B
A1 Mwangangi, J
A1 Bejon, P
A1 Agweyu, A
A1 Williams, TN
A1 Scott, JAG
YR 2022
UL http://medrxiv.org/content/early/2022/10/13/2022.10.12.22281019.abstract
AB Background There is uncertainty about the mortality impact of the COVID-19 pandemic in Africa because of poor ascertainment of cases and limited national civil vital registration. We analysed excess mortality from 1st January 2020-5th May 2022 in a Health and Demographic Surveillance Study in Coastal Kenya where the SARS-CoV-2 seroprevalence reached 75% among adults in March 2022 despite vaccine uptake of only 17%.Methods We modelled expected mortality in 2020-2022 among a population of 306,000 from baseline surveillance data between 2010-2019. We calculated excess mortality as the ratio of observed/expected deaths in 5 age strata for each month and for each national wave of the pandemic. We estimated cumulative mortality risks as the total number of excess deaths in the pandemic per 100,000 population. We investigated observed deaths using verbal autopsy.Finding We observed 16,236 deaths among 3,410,800 person years between 1st January 2010 and 5th May 2022. Across 5 waves of COVID-19 cases during 1st April 2020-16th April 2022, population excess mortality was 4.1% (95% PI -0.2%, 7.9%). Mortality was elevated among those aged ≥65 years at 14.3% (95% PI 7.4%, 21.6%); excess deaths coincided with wave 2 (wild-type), wave 4 (Delta) and wave 5 (Omicron BA1). Among children aged 1-14 years there was negative excess mortality of -20.3% (95% PI -29.8%, -8.1%). Verbal autopsy data showed a transient reduction in deaths from acute respiratory infections in 2020 at all ages. For comparison with other studies, cumulative excess mortality risk for January 2020-December 2021, age-standardized to the Kenyan population, was 47.5/100,000.Interpretation Net excess mortality during the pandemic was substantially lower in Coastal Kenya than in many high income countries. However, adults, aged ≥65 years, experienced substantial excess mortality suggesting that targeted COVID-19 vaccination of older persons may limit further COVID-19 deaths by protecting the residual pool of naive individuals.Funding Wellcome TrustCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in whole by the Wellcome Trust [OXF-COR03-2430]. JAGS and TNW are supported by Wellcome Trust Research Fellowships (214320 and 202800). SPCB is supported by the UK Foreign, Commonwealth and Development Office (FCDO) and Wellcome Trust (220985/Z/20/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethical Review Committee of the Kenya Medical Research Institute (approval number: KEMRI/SERU/CGMR-C/007/3057).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUnderlying individual data include geo-located residence and individual hospital records and hence would be high risk for identifiability. Intermediary data will be published on the Havard dataverse server under a CCBY 4.0 license.